Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 5

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 5
---

  (Level 2)

  Significant
  unobservable inputs
  (Level 3)

    $ 
    $ 
    $ 
    $ 

  Assets

  Treasury bills   classified as cash equivalents
  
   18,087 
   18,087 
    —  
    —  

  Total assets
  
   18,087 
   18,087 
    —  
    —  

  Liabilities

  Derivative warrant liabilities
  
   1,628 
    —  
    —  
   1,628 

  Total liabilities
  
   1,628 
    —  
    —  
   1,628 

   Assets and liabilities measured at fair value on a recurring basis as of March 31, 2025 are as follows: 

  Total

  Quoted
  prices
  in
  active markets
  (Level
  1)

  Significant
  other
  observable
  inputs
  (Level
  2)

  Significant
  unobservable
  inputs
  (Level
  3)

    $ 
    $ 
    $ 
    $ 

  Assets

  Treasury bills classified as cash
  equivalents
  
   21,304 
   21,304 
    —  
    —  

  Total assets
  
   21,304 
   21,204 
    —  
    —  

  Liabilities

  Derivative warrant liabilities
  
   1,141 
    —  
    —  
   1,141 

  Total liabilities
  
   1,141 
    —  
    —  
   1,141 

   There were no changes in valuation techniques or transfers between Levels 1, 2 or 3 during the three months ended June 30, 2025. The Company’s derivative warrant liabilities are measured at fair value on a recurring basis using unobservable inputs that are classified as Level 3 inputs. Refer to Note 6, Stockholders’ Equity, for the valuation techniques and assumptions used in estimating the fair value of the derivative warrant liabilities.

   4. Receivables

 June 30, 2025

   March 31, 2025